26 related articles for article (PubMed ID: 21165404)
1. Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy.
Lee K; Kang I; Mack WJ; Mortimer J; Sattler F; Salem G; Dieli-Conwright CM
Sci Rep; 2020 Apr; 10(1):5839. PubMed ID: 32246106
[TBL] [Abstract][Full Text] [Related]
2. Utility of Matrix Metalloproteinases in the Diagnosis, Monitoring and Prognosis of Ovarian Cancer Patients.
Kicman A; Niczyporuk M; Kulesza M; Motyka J; Ławicki S
Cancer Manag Res; 2022; 14():3359-3382. PubMed ID: 36474934
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of fibulin-5 and matrix metalloproteases in epithelial ovarian cancer.
Manders DB; Kishore HA; Gazdar AF; Keller PW; Tsunezumi J; Yanagisawa H; Lea J; Word RA
Oncotarget; 2018 Mar; 9(18):14251-14267. PubMed ID: 29581841
[TBL] [Abstract][Full Text] [Related]
4. Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer.
Zhang Y; Chen Q
Braz J Med Biol Res; 2017 May; 50(6):e6104. PubMed ID: 28538838
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of matrix metalloproteinase-7 in gastric cancer survival: a meta-analysis.
Soleyman-Jahi S; Nedjat S; Abdirad A; Hoorshad N; Heidari R; Zendehdel K
PLoS One; 2014; 10(4):e0122316. PubMed ID: 25919283
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer: involvement of the matrix metalloproteinases.
Al-Alem L; Curry TE
Reproduction; 2015 Aug; 150(2):R55-64. PubMed ID: 25918438
[TBL] [Abstract][Full Text] [Related]
7. Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10.
Al-Alem LF; McCord LA; Southard RC; Kilgore MW; Curry TE
Biol Reprod; 2013 Sep; 89(3):73. PubMed ID: 23843242
[TBL] [Abstract][Full Text] [Related]
8. Combined detection of serum matrix metalloproteinase 9, acetyl heparinase and cathepsin L in diagnosis of ovarian cancer.
Zhang W; Hu XX; Yang XZ; Wang Q; Cheng H; Wang SM; Hu YL; Yang ZJ; Li L
Chin J Cancer Res; 2012 Mar; 24(1):67-71. PubMed ID: 23359763
[TBL] [Abstract][Full Text] [Related]
9. Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.
Laios A; Mohamed BM; Kelly L; Flavin R; Finn S; McEvoy L; Gallagher M; Martin C; Sheils O; Ring M; Davies A; Lawson M; Gleeson N; D'Arcy T; d'Adhemar C; Norris L; Langhe R; Saadeh FA; O'Leary JJ; O'Toole SA
Int J Mol Sci; 2013 Jan; 14(1):2085-103. PubMed ID: 23340649
[TBL] [Abstract][Full Text] [Related]
10. Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients.
Hałoń A; Nowak-Markwitz E; Donizy P; Matkowski R; Maciejczyk A; Gansukh T; Györffy B; Spaczyński M; Zabel M; Lage H; Surowiak P
J Histochem Cytochem; 2012 Jul; 60(7):491-501. PubMed ID: 22511598
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer.
Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer.
Gershtein ES; Korotkova EA; Shcherbakov AM; Prorokov VV; Golovkov DA; Kushlinskii NE
Bull Exp Biol Med; 2007 Apr; 143(4):459-62. PubMed ID: 18214300
[TBL] [Abstract][Full Text] [Related]
13. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients.
Gunes M; Kemik AS; Pirincci N; Gecit I; Taken K; Yuksel MB; Kaba M; Eryilmaz R
Asian Pac J Cancer Prev; 2013; 14(2):873-6. PubMed ID: 23621254
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.
Gershtein ES; Levkina NV; Digayeva MA; Laktionov KP; Tereshkina IV; Kushlinsky NE
Bull Exp Biol Med; 2010 Oct; 149(5):628-31. PubMed ID: 21165404
[TBL] [Abstract][Full Text] [Related]
15. [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications].
Stettner R; Bogusiewicz M; Rechberger T
Ginekol Pol; 2009 Jan; 80(1):47-53. PubMed ID: 19323060
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors.
Kushlinsky NE; Solovyov YN; Babkina IV; Gershtein ES; Bulicheva IV
Bull Exp Biol Med; 2010 Aug; 149(2):233-5. PubMed ID: 21113498
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
